Bristol-Myers Looks To Block Amgen's Cancer Biosimilar
Bristol-Myers Squibb Co. has sued rival Amgen Inc., seeking a court order blocking the manufacture of a biosimilar to the cancer drug Opdivo while patent rights on the drug's makeup remain...To view the full article, register now.
Already a subscriber? Click here to view full article